journal article·2013-10-22

Cyclic RGD-Linked Polymeric Micelles for Targeted Delivery of Platinum Anticancer Drugs to Glioblastoma through the Blood–Brain Tumor Barrier

Yutaka Miura, Tomoya Takenaka, Kazuko Toh, Shourong Wu, Hiroshi Nishihara, Mitsunobu R. Kano, Yasushi Ino, Takahiro Nomoto, Yu Matsumoto, Hiroyuki Koyama, Horacio Cabral, Nobuhiro Nishiyama, Kazunori Kataoka

ACS Nano· Volume 7· Issue 10
Publisher page

Abstract

Ligand-mediated drug delivery systems have enormous potential for improving the efficacy of cancer treatment. In particular, Arg-Gly-Asp peptides are promising ligand molecules for targeting αvβ3/αvβ5 integrins, which are overexpressed in angiogenic sites and tumors, such as intractable human glioblastoma (U87MG). We here achieved highly efficient drug delivery to U87MG tumors by using a platinum anticancer drug-incorporating polymeric micelle (PM) with cyclic Arg-Gly-Asp (cRGD) ligand molecules. Intravital confocal laser scanning microscopy revealed that the cRGD-linked polymeric micelles (cRGD/m) accumulated rapidly and had high permeability from vessels into the tumor parenchyma compared with the PM having nontargeted ligand, "cyclic-Arg-Ala-Asp" (cRAD). As both cRGD/m- and cRAD-linked polymeric micelles have similar characteristics, including their size, surface charge, and the amount of incorporated drugs, it is likely that the selective and accelerated accumulation of cRGD/m into tumors occurred via an active internalization pathway, possibly transcytosis, thereby producing significant antitumor effects in an orthotopic mouse model of U87MG human glioblastoma.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Cell Adhesion Molecules Research · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan

Division of Tissue Engineering, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan

Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

Department of Translational Pathology, Graduate School of Medicine, Hokkaido University, N15W7, Kita-ku, Sapporo 060-8638, Japan

Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan

Division of Innovative Cancer Therapy, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan

Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan

Polymer Chemistry Division, Chemical Resources Laboratory, Tokyo Institute of Technology, R1-11, 4259 Nagatsuta, Midori-ku, Yokohama 226-8503, Japan

Center for NanoBio Integration, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan

References (50)

Show source-provided references
1. Rat J. S. · Nat. Rev. Cancer · 2003 · 3 · 48910.1038/nrc1121 ↗
2. Arko L. · Pharmacol. Ther. · 2010 · 128 · 110.1016/j.pharmthera.2010.04.015 ↗
3. Mangiola A. · Expert Rev. Neurother. · 2010 · 10 · 50710.1586/ern.09.158 ↗
4. Jain R. K. · Nat. Rev. Neurosci. · 2008 · 8 · 61010.1038/nrn2175 ↗
5. Wen P. Y. · N. Engl. J. Med. · 2008 · 359 · 49210.1056/NEJMra0708126 ↗
6. Avgeropoulos N. G. · Oncologist · 1999 · 4 · 20910.1634/theoncologist.4-3-209 ↗
7. Jones T. S. · Oncogene · 2012 · 31 · 199510.1038/onc.2011.398 ↗
8. Rich J. N. · Nat. Rev. Drug Discovery · 2004 · 3 · 43010.1038/nrd1380 ↗
9. Reardon D. A. · Expert Opin. Drug Discovery · 2011 · 6 · 73910.1517/17460441.2011.584530 ↗
10. Groothuis D. R. · Neuro-Oncology · 2000 · 2 · 4510.1093/neuonc/2.1.45 ↗
11. Ningaraj N. S. · Expert Opin. Drug Delivery · 2006 · 3 · 49910.1517/17425247.3.4.499 ↗
12. Sarin H. · J. Transl. Med. · 2009 · 7 · 7710.1186/1479-5876-7-77 ↗
13. He H. · Biomaterials · 2011 · 32 · 47810.1016/j.biomaterials.2010.09.002 ↗
14. Xin H. · Biomaterials · 2011 · 32 · 429310.1016/j.biomaterials.2011.02.044 ↗
15. Pardridge W. M. · Neuron · 2002 · 36 · 55510.1016/S0896-6273(02)01054-1 ↗
16. Muldoon L. L. · J. Clin. Oncol. · 2007 · 25 · 229510.1200/JCO.2006.09.9861 ↗
17. Liu Y. · Expert Opin. Drug Delivery · 2012 · 9 · 67110.1517/17425247.2012.682726 ↗
18. Chen C. · Eur. J. Neurol. · 2013 · 20 · 22310.1111/j.1468-1331.2012.03778.x ↗
19. Duncan R. · Nat. Rev. Drug Discovery · 2003 · 2 · 34710.1038/nrd1088 ↗
20. Ferrari M. · Nat. Rev. Cancer · 2005 · 5 · 16110.1038/nrc1566 ↗
21. Torchilin V. P. · Nat. Rev. Drug Discovery · 2005 · 4 · 14510.1038/nrd1632 ↗
22. Davis M. E. · Nat. Rev. Drug Discovery · 2008 · 7 · 77110.1038/nrd2614 ↗
23. Kataoka K. · Adv. Drug Delivery Rev. · 2001 · 47 · 11310.1016/S0169-409X(00)00124-1 ↗
24. Nishiyama N. · Pharmacol. Ther. · 2006 · 112 · 63010.1016/j.pharmthera.2006.05.006 ↗
25. Danhier F. · Mol. Pharmaceutics · 2012 · 9 · 296110.1021/mp3002733 ↗
26. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
27. Hobbs S. K. · Proc. Natl. Acad. Sci. U.S.A. · 1998 · 95 · 460710.1073/pnas.95.8.4607 ↗
28. Hynes R. O. · Nat. Med. · 2001 · 8 · 91810.1038/nm0902-918 ↗
29. Hood J. D. · Nat. Rev. Cancer · 2002 · 2 · 9110.1038/nrc727 ↗
30. Desgrosellier J. S. · Nat. Rev. Cancer · 2010 · 10 · 910.1038/nrc2748 ↗
31. Taga T. · Int. J. Cancer · 2002 · 98 · 69010.1002/ijc.10265 ↗
32. Sheldrake H. M. · Curr. Cancer Drug Targets · 2009 · 9 · 51910.2174/156800909788486713 ↗
33. Zhan C. · J. Controlled Release · 2010 · 143 · 13610.1016/j.jconrel.2009.12.020 ↗
34. Zhan C. · J. Controlled Release · 2012 · 160 · 63010.1016/j.jconrel.2012.02.022 ↗
35. Cabral H. · Nat. Nanotechnol. · 2011 · 6 · 81510.1038/nnano.2011.166 ↗
36. Murakami M. · Sci. Transl. Med. · 2011 · 3 · 64ra210.1126/scitranslmed.3001385 ↗
37. Matsumoto Y. · Biomed. Opt. Express · 2010 · 1 · 120910.1364/BOE.1.001209 ↗
38. Nomoto T. · J. Controlled Release · 2011 · 151 · 10410.1016/j.jconrel.2011.02.011 ↗
39. Cabral H. · J. Controlled Release · 2005 · 101 · 22310.1016/j.jconrel.2004.08.022 ↗
40. Cabral H. · J. Controlled Release · 2007 · 121 · 14610.1016/j.jconrel.2007.05.024 ↗
41. Yamada S. · Neurosurgery · 2006 · 59 · 130410.1227/01.NEU.0000245622.70344.BE ↗
42. Carter A. · J. Natl. Cancer Inst. · 2010 · 102 · 67510.1093/jnci/djq186 ↗
43. Fink K. · J. Clin. Oncol. · 2010 · 28 · 182s10.1200/jco.2010.28.15_suppl.2010 ↗
44. Mikkelsen T. · Int. J. Cancer · 2009 · 124 · 271910.1002/ijc.24240 ↗
45. Nabors L. B. · J. Clin. Oncol. · 2007 · 25 · 165110.1200/JCO.2006.06.6514 ↗
46. Morita K. · Exp. Dermatol. · 2003 · 12 · 28910.1034/j.1600-0625.2003.120309.x ↗
47. Cooper I. · Methods Mol. Biol. · 2011 · 762 · 34710.1007/978-1-61779-185-7_25 ↗
48. Jiao H. · J. Mol. Neurosci. · 2011 · 44 · 13010.1007/s12031-011-9496-4 ↗
49. Stewart P. A. · J. Neurosurg. · 1987 · 67 · 69710.3171/jns.1987.67.5.0697 ↗
50. Stewart P. A. · Cell. Mol. Neurobiol. · 2000 · 20 · 14910.1023/A:1007026504843 ↗